Physician profile
Simone Stalling
NPI 1922310911
$6,665.99
in general payments reported to CMS, 2019-2025
26 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $320 · 2021: $658 · 2022: $871 · 2023: $1,457 · 2024: $1,673 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,221.73 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $841.46 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $788.20 | 2019-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $746.31 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Janssen Biotech, INC. | $680.60 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $321.81 | 2019-2024 | Dupixent |
| Amgen INC. | $296.27 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $277.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $260.71 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $258.77 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $257.64 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $256.03 | 2023-2024 | Zoryve |
| Genzyme Corporation | $254.98 | 2023-2025 | |
| Dermavant Sciences, INC. | $211.97 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $199.03 | 2020-2024 | Cabtreo |
| Leo Pharma INC. | $171.93 | 2020-2025 | Anzupgo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $154.35 | 2019-2025 | |
| Organon LLC | $145.08 | 2025 | Vtama |
| Epi Health, LLC | $129.13 | 2021-2022 | |
| Merz North America, INC. | $100.54 | 2022-2025 | |
| Celgene Corporation | $83.94 | 2019 | |
| Incyte Corporation | $65.63 | 2021-2025 | Opzelura |
| Almirall LLC | $63.78 | 2020-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $28.11 | 2020 | |
| Ucb, INC. | $27.77 | 2024 | Bimzelx |
| Sandoz INC. | $25.00 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $19.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Stalling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.